These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 21817145)

  • 21. Initial experience with the novel patent foramen ovale occlusion device Nit-Occlud® in patients with stroke or transient ischemic attack.
    Steinberg DH; Bertog SC; Momberger J; Franke J; Hofmann I; Renkhoff K; Joy S; Vaskelyte L; Sievert H
    Catheter Cardiovasc Interv; 2015 Jun; 85(7):1262-7. PubMed ID: 24948394
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Secondary prevention after cryptogenic cerebrovascular events in patients with patent foramen ovale.
    Schuchlenz HW; Weihs W; Berghold A; Lechner A; Schmidt R
    Int J Cardiol; 2005 May; 101(1):77-82. PubMed ID: 15860387
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recurrent events after percutaneous closure of patent foramen ovale.
    Wallenborn J; Bertog SC; Franke J; Steinberg DH; Majunke N; Wilson N; Wunderlich N; Sievert H
    Catheter Cardiovasc Interv; 2013 Oct; 82(4):541-6. PubMed ID: 22707325
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antiplatelet effects of clopidogrel and aspirin after interventional patent foramen ovale/ atrium septum defect closure.
    Polzin A; Dannenberg L; Sophia Popp V; Kelm M; Zeus T
    Platelets; 2016 Jun; 27(4):317-21. PubMed ID: 26556101
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ten years of experience with closure of persistent foramen ovale: patient characteristics and outcomes.
    Lehmann R; Fichtlscherer S; Baldauf H; Schächinger V; Auch-Schwelck W; Zeiher AM; Teupe C
    J Cardiol; 2014 Aug; 64(2):113-6. PubMed ID: 24480741
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Percutaneous device closure of patent foramen ovale in patients with presumed cryptogenic stroke or transient ischemic attack: the Mayo Clinic experience.
    Ford MA; Reeder GS; Lennon RJ; Brown RD; Petty GW; Cabalka AK; Cetta F; Hagler DJ
    JACC Cardiovasc Interv; 2009 May; 2(5):404-11. PubMed ID: 19463462
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Age as a determinant of adverse events in medically treated cryptogenic stroke patients with patent foramen ovale.
    Homma S; DiTullio MR; Sacco RL; Sciacca RR; Mohr JP;
    Stroke; 2004 Sep; 35(9):2145-9. PubMed ID: 15232117
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low cerebrovascular event rate in subjects with patent foramen ovale and different clinical presentations: results from a prospective non randomized study on a population including patients with and without patent foramen ovale closure.
    Faggiano P; Frattini S; Piovesana P; Lorusso R; Chiari E; Scolari F; Padovani A; Cas LD
    Int J Cardiol; 2012 Apr; 156(1):47-52. PubMed ID: 21112103
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Study design of the CLOSURE I Trial: a prospective, multicenter, randomized, controlled trial to evaluate the safety and efficacy of the STARFlex septal closure system versus best medical therapy in patients with stroke or transient ischemic attack due to presumed paradoxical embolism through a patent foramen ovale.
    Furlan AJ; Reisman M; Massaro J; Mauri L; Adams H; Albers GW; Felberg R; Herrmann H; Kar S; Landzberg M; Raizner A; Wechsler L;
    Stroke; 2010 Dec; 41(12):2872-83. PubMed ID: 21051670
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcome after percutaneous closure of a patent foramen ovale using the Intrasept device: a multi-centre study.
    Luermans JG; Post MC; Schräder R; Sluysmans T; Vydt T; Vermeersch P; Chessa M; Onorato E; Goy JJ; Budts WI
    Catheter Cardiovasc Interv; 2008 May; 71(6):822-8. PubMed ID: 18324695
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of Discontinuation of Antithrombotic Therapy Following Closure of Patent Foramen Ovale in Patients With Cryptogenic Embolism.
    Wintzer-Wehekind J; Alperi A; Houde C; Côté JM; Guimaraes LFC; Côté M; Rodés-Cabau J
    Am J Cardiol; 2019 May; 123(9):1538-1545. PubMed ID: 30792001
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of patent foramen ovale closure for prevention on recurrent stroke or transient ischemic attack in selected patients with cryptogenic stroke.
    Kim M; Kim S; Moon J; Oh PC; Park YM; Shin DH; Lee YB; Lee JY; Hwang HY; Kang WC
    J Interv Cardiol; 2018 Jun; 31(3):368-374. PubMed ID: 28833599
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical outcomes of secondary prevention strategies for young patients with cryptogenic stroke and patent foramen ovale.
    Danese A; Stegagno C; Tomelleri G; Piccoli A; Turri G; Carletti M; Variola A; Anselmi M; Mazzucco S; Ferrara A; Bovi P; Micheletti N; Cappellari M; Monaco S; Vassanelli C; Ribichini F;
    Acta Cardiol; 2017 Aug; 72(4):410-418. PubMed ID: 28705105
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Stroke and patent foramen ovale in young individuals.
    Piechowski-Jozwiak B; Bogousslavsky J
    Eur Neurol; 2013; 69(2):108-17. PubMed ID: 23207510
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Is Patent Foramen Ovale Closure More Effective Than Medical Therapy in Preventing Stroke Recurrence in Patients With Cryptogenic Stroke?: A Critically Appraised Topic.
    Valencia-Sanchez C; Fortuin FD; Sweeney JP; Ingall TJ; Marks LA; Wingerchuk DM; O'Carroll CB
    Neurologist; 2018 Sep; 23(5):175-180. PubMed ID: 30169372
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke.
    Carroll JD; Saver JL; Thaler DE; Smalling RW; Berry S; MacDonald LA; Marks DS; Tirschwell DL;
    N Engl J Med; 2013 Mar; 368(12):1092-100. PubMed ID: 23514286
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term results of a randomized trial comparing three different devices for percutaneous closure of a patent foramen ovale.
    Hornung M; Bertog SC; Franke J; Id D; Taaffe M; Wunderlich N; Vaskelyte L; Hofmann I; Sievert H
    Eur Heart J; 2013 Nov; 34(43):3362-9. PubMed ID: 23842846
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outcome of patients with cryptogenic stroke and patent foramen ovale.
    Nedeltchev K; Arnold M; Wahl A; Sturzenegger M; Vella EE; Windecker S; Meier B; Mattle HP
    J Neurol Neurosurg Psychiatry; 2002 Mar; 72(3):347-50. PubMed ID: 11861693
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Patent foramen ovale closure versus medical therapy in cases with cryptogenic stroke, meta-analysis of randomized controlled trials.
    Abo-Salem E; Chaitman B; Helmy T; Boakye EA; Alkhawam H; Lim M
    J Neurol; 2018 Mar; 265(3):578-585. PubMed ID: 29356972
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness of percutaneous patent foramen ovale closure as secondary stroke prevention.
    Tirschwell DL; Turner M; Thaler D; Choulerton J; Marks D; Carroll J; MacDonald L; Smalling RW; Koullick M; Gu NY; Saver JL
    J Med Econ; 2018 Jul; 21(7):656-665. PubMed ID: 29564942
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.